Compare GTBP & SOBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTBP | SOBR |
|---|---|---|
| Founded | 1965 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.4M |
| IPO Year | N/A | N/A |
| Metric | GTBP | SOBR |
|---|---|---|
| Price | $0.66 | $1.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 69.2K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $364,164.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 98.07 |
| 52 Week Low | $0.54 | $1.27 |
| 52 Week High | $4.10 | $42.00 |
| Indicator | GTBP | SOBR |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 40.18 |
| Support Level | $0.58 | $1.43 |
| Resistance Level | $0.82 | $2.17 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 32.15 | 59.17 |
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.